rituximab + autologous dendritic cells + radiotherapy

This investigational combination therapy, developed by Oslo University Hospital, is an in situ cancer vaccine approach for the treatment of indolent non-Hodgkin lymphoma (NHL), particularly follicular lymphoma. The therapeutic regimen, evaluated in the Phase II Lymvac-1 trial, consists of three integrated components: low-dose local radiotherapy (8 Gy) to a single tumor lesion, followed by intratumoral injections of the anti-CD20 monoclonal antibody rituximab and autologous dendritic cells. The radiotherapy is intended to induce immunogenic cell death and release tumor-associated antigens. The injected dendritic cells then capture these antigens and migrate to regional lymph nodes to prime a systemic T-cell-mediated anti-tumor immune response. Rituximab is included to deplete local B-cells and potentially enhance antigen uptake by dendritic cells through Fc-receptor-mediated mechanisms, aiming to achieve both local control and a systemic (abscopal) effect against disseminated disease.

Other names

rituximab + DC-Oslo University Hospital-indolent non-Hodgkin lymphomaRadiotherapy, rituximab and DCLymvac-1 protocolLymvac1 protocolLymvac 1 protocolIntratumoral rituximab and autologous dendritic cells